Short Interest in Profusa, Inc. (NASDAQ:PFSA) Grows By 1,666.7%

Profusa, Inc. (NASDAQ:PFSA) saw a large growth in short interest in April. As of April 30th, there was short interest totaling 665,135 shares, a growth of 1,666.7% from the April 15th total of 37,649 shares. Approximately 17.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,488,159 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research report on Friday, March 27th. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Profusa Price Performance

PFSA traded down $0.04 during trading on Monday, reaching $0.48. 191,698 shares of the company’s stock were exchanged, compared to its average volume of 1,591,315. Profusa has a one year low of $0.41 and a one year high of $180.00. The stock has a fifty day moving average price of $0.74.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.